NBIX
NASD Neurocrine Biosciences, Inc.$136.99 ↑ +0.04 (+0.03%) Trading Up from the previous close of $136.95
- YTD change
- -3.41%
- vs 20-day SMA
- -2.85%
- vs 200-day SMA
- -6.85%
Price ranges
Price & Performance
+8.54 (+6.65%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 26.4% away from all-time highs of $186.12
- NBIX is down 3% since the beginning of the year
- NBIX is down 0% over the past 12 months
- NBIX is down 10% over the past 1 month
- 6% of all NBIX investors are betting against NBIX
NBIX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -0.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -3.02%
- vs 8-day SMA
- -2.33%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
